- Home
- COP vs TMO Comparison
COP vs TMO Comparison
Compare COP & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COP | TMO |
|---|---|---|
| Founded | 1917 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Industrial Machinery/Components |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1B | 164.3B |
| IPO Year | 2005 | 1996 |
Fundamental Metrics
Financial Performance| Metric | COP | TMO |
|---|---|---|
| Price | $115.30 | $453.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 18 |
| Target Price | $123.65 | ★ $636.00 |
| AVG Volume (30 Days) | ★ 6.5M | 2.2M |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.62% | 0.40% |
| EPS Growth | N/A | ★ 7.32 |
| EPS | 1.78 | ★ 4.43 |
| Revenue | ★ $58,944,000,000.00 | $20,918,000,000.00 |
| Revenue This Year | $6.88 | $6.55 |
| Revenue Next Year | N/A | $5.11 |
| P/E Ratio | ★ $65.49 | $101.26 |
| Revenue Growth | 7.67 | ★ 14.47 |
| 52 Week Low | $84.34 | $385.46 |
| 52 Week High | $135.87 | $643.99 |
Technical Indicators
Market Signals| Indicator | COP | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 39.90 | 43.79 |
| Support Level | $112.95 | $435.27 |
| Resistance Level | $122.50 | $502.20 |
| Average True Range (ATR) | 2.78 | 12.35 |
| MACD | -0.34 | 1.12 |
| Stochastic Oscillator | 11.88 | 41.17 |
Price Performance
Historical ComparisonAbout COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).